AFP and neoplasm: Furthermore, patients’ clinical characteristics such as tumor stage and alpha-fetoprotein levels, severity of AEs, reasons for treatment discontinuation, and physicians’ rationales for dosage decisions are not available and thus, could not be described for each cohort.